Stockscreener 앱 받기
1.65
3.12%
0.05
전일 마감가:
$1.60
열려 있는:
$1.59
하루 거래량:
293.49K
Relative Volume:
0.62
시가총액:
$24.48M
수익:
$709.00K
순이익/손실:
$-21.41M
주가수익비율:
-1.7368
EPS:
-0.95
순현금흐름:
$-19.70M
1주 성능:
-11.29%
1개월 성능:
-10.81%
6개월 성능:
-32.65%
1년 성능:
-89.81%
1일 변동 폭
$1.59
$1.72
1주일 범위
$1.59
$1.8899
52주 변동 폭
$0.7707
$14.80
Longeveron Inc Stock (LGVN) Company Profile
명칭
Longeveron Inc
전화
305-302-7158
주소
1951 NW 7TH AVENUE, MIAMI
LGVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
1.65 | 24.48M | 709.00K | -21.41M | -19.70M | -10.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-06 | 개시 | ROTH MKM | Buy |
Longeveron Inc 주식(LGVN)의 최신 뉴스
Longeveron to Present at Biotech Showcase 2025 - The Manila Times
Longeveron CEO to Present at Biotech Showcase 2025: Spotlight on Regenerative Medicine Breakthroughs - StockTitan
Longeveron (NASDAQ:LGVN) Upgraded at Roth Capital - Defense World
Longeveron initiated with a Buy at Roth MKM - Yahoo Finance
Roth MKM Initiates Coverage of Longeveron (LGVN) with Buy Recommendation - MSN
Longeveron director Baluch Khoso sells $2,588 in stock By Investing.com - Investing.com Canada
Longeveron director Baluch Khoso sells $2,588 in stock - Investing.com
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024 - Marketscreener.com
Longeveron FY2024 EPS Forecast Increased by HC Wainwright - Defense World
Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright - Defense World
H.C. Wainwright reiterates Buy on Longeveron stock, raises target by 25% on trial progress - Investing.com India
Longeveron Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Longeveron stock opened 100% up on Wednesday: explore why - MSN
We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Longeveron Inc - GuruFocus.com
The Escalator: Sanofi, Longeveron, Geron and more - MM+M Online
Earnings call: Longeveron Q3 2024 results show promise in regenerative medicine - Investing.com
Longeveron Inc. (NASDAQ:LGVN) Q3 2024 Earnings Call Transcript - Insider Monkey
Longeveron reports Q3 EPS (34c), consensus (44c) - TipRanks
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
LGVNLongeveron Inc. Latest Stock News & Market Updates - StockTitan
A Look Ahead: Longeveron's Earnings Forecast - Benzinga
Longeveron names Devin Blass as new CTO - Investing.com
Longeveron names Devin Blass as new CTO By Investing.com - Investing.com UK
Longeveron Taps Devin Blass As CTO And SVP Of CMC - Contract Pharma
Longeveron Taps Devin Blass As CTO And SVP Of Chemistry, Manufacturing And Controls - Contract Pharma
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) - The Manila Times
Longeveron Strengthens Leadership: Key Executive Hire Ahead of Critical BLA Submission | LGVN Stock News - StockTitan
Earnings To Watch: Longeveron Inc (LGVN) Reports Q3 2024 Result - Yahoo Finance
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - StockTitan
Peeling Back The Layers: Exploring Longeveron Through Analyst Insights - Benzinga
Longeveron presents Alzheimer's therapy data at CTAD24 - Investing.com
Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) - The Manila Times
Longeveron presents Alzheimer's therapy data at CTAD24 By Investing.com - Investing.com UK
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) - StockTitan
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting - ForexTV.com
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting - GlobeNewswire Inc.
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Why has Longeveron stock tripled in two days? - MSN
Euro FX (E6N18) Quote - The Globe and Mail
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Scholastic Corp (SCHL-Q) QuotePress Release - The Globe and Mail
LGVN’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
LGVNRLongeveron Inc. Latest Stock News & Market Updates - StockTitan
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) - ForexTV.com
Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) - The Manila Times
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected - GlobeNewswire
Longeveron Inc (LGVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):